Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05243680 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 641
- Enrollment target
NCT05243680 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 641 participants.
The verdict
NCT05243680, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 641 participants
- Enrollment target
Study Summary
The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206713 or 213744.
Interventions
- BIOLOGICAL GSK3511294 (Depemokimab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 641 participants |
| Start Date | 2022-03-01 |
| Est. Completion | 2025-05-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05243680
The ClinicalTrials.gov registry entry for NCT05243680 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 641 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK3511294 (Depemokimab) is the first listed.
NCT05243680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05243680 about?
NCT05243680 is a clinical study titled "An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)". The purpose of this open-label 12-month extension study is to continue to characterize the long-term safety, efficacy and immunogenic profile of GSK3511294 (Depemokimab) in participants with severe asthma with an eosinophilic phenotype following completion of clinical studies 206713 or 213744.
What is the current status of trial NCT05243680?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 641 participants. The study started on 2022-03-01. Estimated completion is 2025-05-19.
What interventions are being tested in trial NCT05243680?
The interventions under investigation include: GSK3511294 (Depemokimab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05243680?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.